Bristol-Myers Squibb Cuts FY26 EPS Guidance to $6.35-$6.55, Raises Revenue Outlook to $49.75B-$50.25B; BMY Rises 2.19%

Bristol-Myers Squibb Co. (BMY) lowered its full-year 2026 earnings guidance on Thursday while raising its annual revenue forecast, sending shares up 2.19% to $61.94 in pre-market trading on the NYSE. For fiscal 2026, the drugmaker now projects earnings of about $6.35 to $6.55 per share on worldwide revenues of roughly $49.75 billion to $50.25 billion. The guidance includes a $0.60 per share net impact from acquired IPRD charges and licensing income. The company previously expected earnings of about $6.75 to $7.00 per share on revenues of $49.0 billion to $50.0 billion. Bristol-Myers also said it continues to expect total worldwide Eliquis revenues to grow 20% to 25% in 2026 compared with 2025. The revised outlook accompanied the company's third-quarter financial results.